← Human Trials & Peer-Reviewed Studies
Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration
Plain-language guide to PMID 17466972 (2007): controlled clinical trial study of Vasopressin in 2 patients.
Key Facts
- PMID
- 17466972
- Journal
- European journal of pharmacology
- Year
- 2007
- Study type
- Controlled Clinical Trial
- Authors
- Wilting I et al. (9 authors)
- DOI
- 10.1016/j.ejphar.2007.03.038
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vasopressin in this controlled clinical trial publication.
The aim of the present study was to investigate the kidney response to minimal and maximal stimulation of the kidney urine concentrating mechanism by measuring urine osmolality, and urine levels of cAMP and AQP-2 in urine of patients under long-term lithium treatment.
Why It Was Studied
The exact mechanism of lithium-induced NDI in man is unknown.
The kidney urinary 3',5'-cyclic adenosine monophosphate (cyclic AMP), aquaporin-2 levels and urine osmolality were determined during a situation of minimal kidney urine concentrating activity (induced by water loading) and during a situation following maximal stimulation of kidney urine concentrating activity (induced by 1-desamino-8-D-arginine-vasopressin).
Who Took Part
According to the abstract, 2 patients were involved.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
Twenty patients under long-term lithium treatment were included.
What Was Measured
The kidney urinary 3',5'-cyclic adenosine monophosphate (cyclic AMP), aquaporin-2 levels and urine osmolality were determined during a situation of minimal kidney urine concentrating activity (induced by water loading) and during a situation following maximal stimulation of kidney urine concentrating activity (induced by 1-desamino-8-D-arginine-vasopressin).
PubMed files the paper under topics including Antimanic Agents, Aquaporin 2, Cyclic AMP, Deamino Arginine Vasopressin, Diabetes Insipidus, Nephrogenic, Lithium Compounds and Osmolar Concentration.
What This Means in Plain Language
This is a controlled clinical trial of Vasopressin in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2007 (European journal of pharmacology), a journal based in Netherlands.
More context: the Vasopressin compound page, all human trials.
Our Notes on the Compound
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.